ABOUT THE PRODUCT
GRN-300 is a first-in-class small molecule SIK2/3 inhibitor currently in a Phase 1 clinical trial for ovarian cancer and triple-negative breast cancer (TNBC).
Information is owner-confirmed
Last updated Yesterday
Price range
Other products/services from Greenfire Bio
PCLX-001
Pharmaceutical
N/A
Greenfire Bio
United States (US)